In just six years, our Target ALS Innovation Ecosystem has given rise to a new collaborative research community and led to the development of an array of therapeutic approaches with biologic rationale. Many of these new approaches leverage next-generation technology never before deployed in ALS research ranging from antisense oligonucleotides to revolutionary genome editing. Within this section, we provide a snapshot of our ecosystem at work.
100+ Research Collaborations
The word is spreading. Hundreds of researchers with expertise in diverse areas like high-throughput functional genomics, medicinal chemistry and stem cell biology have become committed collaborators within the ALS research community.
See our research collaboration at work
50+ Pharma/Biotech Programs
Our ecosystem has enabled the industry to view ALS drug development as an increasingly tractable area for investment. Over 50 ALS drug development programs are now in place across the industry – compared to just five when Target ALS was launched.
See how industry collaboration is making an impact
12+ Therapeutic Options
Our ecosystem has accelerated the validation of a plethora of promising new drug targets. More than 12 therapeutic approaches have emerged from this work, and many of these are poised for clinical trials.
See what our Founder says about our progress.